| Outcome Measures: |
Primary: Mean Change From Baseline in Glycosylated Haemoglobin A1c (HbA1c) at Week 26, Calculated as an estimate of the mean change from baseline in glycosylated haemoglobin A1c (HbA1c) at Week 26., Week 0, Week 26|Mean Change From Baseline in Glycosylated Haemoglobin A1c (HbA1c) at Week 52, Calculated as an estimate of the mean change from baseline in glycosylated haemoglobin A1c (HbA1c) at Week 52., Week 0, Week 52|Mean Change From Baseline in Glycosylated Haemoglobin A1c (HbA1c) at Week 78, Calculated as an estimate of the mean change from baseline in glycosylated haemoglobin A1c (HbA1c) at Week 78., Week 0, Week 78|Mean Change in Glycosylated Haemoglobin A1c (HbA1c) From Week 52 to Week 78, Mean Change in Glycosylated Haemoglobin A1c (HbA1c) from Week 52 to Week 78, Week 52, Week 78 | Secondary: Percentage of Subjects Achieving Treatment Target of HbA1c < 7.0% at Week 26, Calculated as the percentage of subjects achieving treatment target of HbA1c \< 7.0% at Week 26, Week 0, Week 26|Percentage of Subjects Achieving Treatment Target of HbA1c < 7.0% at Week 52, Calculated as an estimate of the percentage of subjects achieving treatment target of HbA1c \< 7.0% at Week 52, Week 0, Week 52|Percentage of Subjects Achieving Treatment Target of HbA1c < 7.0% at Week 78, Calculated as an estimate of the percentage of subjects achieving treatment target of HbA1c \< 7.0% at Week 78. Based on the FAS., Week 0, Week 78|Percentage of Subjects Achieving Treatment Target of HbA1c < 7.0% at Week 78, Calculated as an estimate of the percentage of subjects achieving treatment target of HbA1c \< 7.0% at Week 78. Based on the extension 2 FAS., Week 0, Week 78|Percentage of Subjects Achieving Treatment Target of HbA1c =< 6.5% at Week 26, Calculated as the percentage of subjects achieving treatment target of HbA1c =\< 6.5% at Week 26, Week 0, Week 26|Percentage of Subjects Achieving Treatment Target of HbA1c =< 6.5% at Week 52, Calculated as an estimate of the percentage of subjects achieving treatment target of HbA1c =\< 6.5% at Week 52, Week 0, Week 52|Percentage of Subjects Achieving Treatment Target of HbA1c =< 6.5% at Week 78, Calculated as an estimate of the percentage of subjects achieving treatment target of HbA1c =\< 6.5% at Week 78. Based on the FAS., Week 0, Week 78|Percentage of Subjects Achieving Treatment Target of HbA1c =< 6.5% at Week 78, Calculated as an estimate of the percentage of subjects achieving treatment target of HbA1c =\< 6.5% at Week 78. Based on the extension 2 FAS., Week 0, Week 78|Mean Change From Baseline in Body Weight at Week 26, Calculated as an estimate of the mean change from baseline in body weight at Week 26., Week 0, Week 26|Mean Change From Baseline in Body Weight at Week 52, Calculated as an estimate of the mean change from baseline in body weight at Week 52., Week 0, Week 52|Mean Change in Body Weight From Week 52 to Week 78, Mean change in body weight from Week 52 to Week 78., Week 52, Week 78|Mean Change From Baseline in Fasting Plasma Glucose (FPG) at Week 26, Calculated as an estimate of the mean change from baseline in fasting plasma glucose (FPG) at Week 26., Week 0, Week 26|Mean Change From Baseline in Fasting Plasma Glucose (FPG) at Week 52, Calculated as an estimate of the mean change from baseline in fasting plasma glucose (FPG) at Week 52., Week 0, Week 52|Mean Change From Baseline in Fasting Plasma Glucose (FPG) at Week 78, Calculated as an estimate of the mean change in fasting plasma glucose (FPG) from baseline to Week 78., Week 0, Week 78|Mean Change in Fasting Plasma Glucose (FPG) From Week 52 to Week 78, Mean change in fasting plasma glucose (FPG) Week 52 to Week 78., Week 52, Week 78|Mean Change From Baseline in Beta-cell Function at Week 26, Calculated as an estimate of the mean change from baseline in beta-cell function at Week 26. Derived from fasting plasma glucose (FPG) and fasting insulin using the homeostatic model assessment (HOMA) method with the assumption that normal-weight subjects aged under 35 years have a 100% beta-cell function (HOMA-B)., Week 0, Week 26|Mean Change From Baseline in Beta-cell Function at Week 52, Calculated as an estimate of the mean change from baseline in beta-cell function at Week 52. Derived from fasting plasma glucose (FPG) and fasting insulin using the homeostatic model assessment (HOMA) method with the assumption that normal-weight subjects aged under 35 years have a 100% beta-cell function (HOMA-B)., Week 0, Week 52|Mean Change in Beta-cell Function From Week 52 to Week 78, Mean change in beta-cell function from Week 52 to Week 78. Derived from fasting plasma glucose (FPG) and fasting insulin using the homeostatic model assessment (HOMA) method with the assumption that normal-weight subjects aged under 35 years have a 100% beta-cell function (HOMA-B)., Week 52, Week 78|Mean Change From Baseline in Total Cholesterol at Week 26, Calculated as an estimate of the mean change from baseline in total cholesterol at Week 26., Week 0, Week 26|Mean Change From Baseline in Total Cholesterol at Week 52, Calculated as an estimate of the mean change from baseline in total cholesterol at Week 52., Week 0, Week 52|Mean Change in Total Cholesterol From Week 52 to Week 78, Mean change in total cholesterol from Week 52 to Week 78, Week 52, Week 78|Mean Change From Baseline in Low-density Lipoprotein-cholesterol (LDL-C) at Week 26, Calculated as an estimate of the mean change in low-density lipoprotein-cholesterol (LDL-C) at Week 26., Week 0, Week 26|Mean Change From Baseline in Low-density Lipoprotein-cholesterol (LDL-C) at Week 52, Calculated as an estimate of the mean change in low-density lipoprotein-cholesterol (LDL-C) at Week 52., Week 0, Week 52|Mean Change in Low-density Lipoprotein-cholesterol (LDL-C) From Week 52 to Week 78, Mean change in low-density lipoprotein-cholesterol (LDL-C) from week 52 to Week 78., Week 52, Week 78|Mean Change From Baseline in High-density Lipoprotein-cholesterol (HDL-C) at Week 26, Calculated as an estimate of the mean change from baseline in high-density lipoprotein-cholesterol (HDL-C) at Week 26., Week 0, Week 26|Mean Change From Baseline in High-density Lipoprotein-cholesterol (HDL-C) at Week 52, Calculated as an estimate of the mean change from baseline in high-density lipoprotein-cholesterol (HDL-C) at Week 52., Week 0, Week 52|Mean Change in High-density Lipoprotein-cholesterol (HDL-C) From Week 52 to Week 78, Mean change in high-density lipoprotein-cholesterol (HDL-C) from Week 52 to Week 78., Week 52, Week 78|Mean Change From Baseline in Very Low-density Lipoprotein-cholesterol (VLDL-C) at Week 26, Calculated as an estimate of the change from baseline in very low-density lipoprotein-cholesterol (VLDL-C) at Week 26., Week 0, Week 26|Mean Change From Baseline in Very Low-density Lipoprotein-cholesterol (VLDL-C) at Week 52, Calculated as an estimate of the change from baseline in very low-density lipoprotein-cholesterol (VLDL-C) at Week 52., Week 0, Week 52|Mean Change in Very Low-density Lipoprotein-cholesterol (VLDL-C) at Week 52 to Week 78, Mean change in very low-density lipoprotein-cholesterol (VLDL-C) from Week 52 to Week 78., Week 52, Week 78|Mean Change From Baseline in Triglycerides (TG) at Week 26, Calculated as an estimate of the change from baseline in triglycerides (TG) at Week 26., Week 0, Week 26|Mean Change From Baseline in Triglycerides (TG) at Week 52, Calculated as an estimate of the change from baseline in triglycerides (TG) at Week 52., Week 0, Week 52|Mean Change in Triglycerides (TG) From Week 52 to Week 78, Mean change in triglycerides (TG) from Week 52 to Week 78., Week 52, Week 78|Mean Change From Baseline in Free Fatty Acids (FFA) at Week 26, Calculated as an estimate of the change from baseline in free fatty acids (FFA) at Week 26., Week 0, Week 26|Mean Change From Baseline in Free Fatty Acids (FFA) at Week 52, Calculated as an estimate of the change from baseline in free fatty acids (FFA) at Week 52., Week 0, Week 52|Mean Change in Free Fatty Acids (FFA) From Week 52 to Week 78, Mean change in free fatty acids (FFA) from Week 52 to Week 78., Week 52, Week 78|Mean Change From Baseline in Apolipoprotein B at Week 26, Calculated as an estimate of the change from baseline in apolipoprotein B (ApoB) at Week 26., Week 0, Week 26|Mean Change From Baseline in Apolipoprotein B at Week 52, Calculated as an estimate of the change from baseline in apolipoprotein B (ApoB) at Week 52., Week 0, Week 52|Mean Change in Apolipoprotein B From Week 52 to Week 78, Mean change in apolipoprotein B (ApoB) from Week 52 to Week 78., Week 52, Week 78|Mean Change From Baseline in Highly Sensitive C-reactive Protein (hsCRP) at Week 26, Calculated as an estimate of the mean change from baseline in highly sensitive C-reactive protein (hsCRP) at week 26., Week 0, Week 26|Mean Change From Baseline in Plasminogen Activator Inhibitor-1 (PAI-1) at Week 26., Calculated as an estimate of the mean change from baseline in plasminogen activator inhibitor-1 (PAI-1) at Week 26., Week 0, Week 26|Mean Change From Baseline in Interleukin-6 (IL-6) at Week 26., Calculated as an estimate of the mean change from baseline in interleukin-6 (IL-6) at Week 26., Week 0, Week 26|Mean Change From Baseline in N-terminal Pro B-type Natriuretic Peptide (NT-proBNP) at Week 26., Calculated as an estimate of the mean change from baseline in N-terminal pro B-type Natriuretic Peptide (NT-proBNP) at Week 26., Week 0, Week 26|Mean Change From Baseline in Adiponectin at Week 26., Calculated as an estimate of the mean change from baseline in Adiponectin at Week 26., Week 0, Week 26|Mean Change From Baseline in Tumour Necrosis Factor Alpha (TNF-alpha) at Week 26., Calculated as an estimate of the mean change from baseline in Tumour Necrosis Factor Alpha (TNF-alpha) at Week 26., Week 0, Week 26|Mean Change From Baseline in Von Willebrand Factor (vWf) at Week 26., Calculated as an estimate of the mean change from baseline in von Willebrand Factor (vWf) at Week 26. vWf is a blood glycoprotein involved in haemostasis., Week 0, Week 26|Mean Change From Baseline in Waist to Hip Ratio at Week 26., Calculated as an estimate of the mean change from baseline in Waist to Hip Ratio at Week 26. The measure is assessed as the circumference of the waist divided by the circumference of the hip., Week 0, Week 26|Mean Change From Baseline in Waist to Hip Ratio at Week 52, Calculated as an estimate of the mean change from baseline in Waist to Hip Ratio at Week 52. The measure is assessed as the circumference of the waist divided by the circumference of the hip., Week 0, Week 52|Mean Change in Waist to Hip Ratio From Week 52 to Week 78, Mean change in Waist to Hip Ratio from Week 52 to Week 78. The measure is assessed as the circumference of the waist divided by the circumference of the hip., Week 52, Week 78|Mean Change From Baseline in Waist Circumference at Week 26., Calculated as an estimate of the mean change from baseline in Waist Circumference at Week 26, Week 0, Week 26|Mean Change From Baseline in Waist Circumference at Week 52, Calculated as an estimate of the mean change from baseline in Waist Circumference at Week 52., Week 0, Week 52|Mean Change in Waist Circumference From Week 52 to Week 78, Mean change in Waist Circumference from Week 52 to Week 78., Week 52, Week 78|Mean Change From Baseline in Systolic Blood Pressure (SBP) at Week 26, Calculated as an estimate of the mean change from baseline in Systolic Blood Pressure (SBP) at Week 26, Week 0, Week 26|Mean Change From Baseline in Systolic Blood Pressure (SBP) at Week 52, Calculated as an estimate of the mean change from baseline in systolic blood pressure (SBP) at Week 52., Week 0, Week 52|Mean Change in Systolic Blood Pressure (SBP) From Week 52 to Week 78, Mean change in systolic blood pressure (SBP) from Week 52 to Week 78., Week 52, Week 78|Mean Change From Baseline in Diastolic Blood Pressure (DBP) at Week 26, Calculated as an estimate of the mean change from baseline in diastolic blood pressure (DBP) at Week 26., Week 0, Week 26|Mean Change From Baseline in Diastolic Blood Pressure (DBP) at Week 52, Calculated as an estimate of the mean change from baseline in diastolic blood pressure (DBP) at Week 52., Week 0, Week 52|Mean Change in Diastolic Blood Pressure (DBP) From Week 52 to Week 78, Mean change in diastolic blood pressure (DBP) from Week 52 to Week 78., Week 52, Week 78|Mean Change From Baseline in Pulse at Week 26, Calculated as an estimate of the mean change from baseline in pulse at Week 26., Week 0, Week 26|Mean Change From Baseline in Pulse at Week 52, Calculated as an estimate of the mean change from baseline in pulse at Week 52., Week 0, Week 52|Mean Change in Pulse From Week 52 to Week 78, Mean change in pulse from Week 52 to Week 78., Week 52, Week 78|Mean Change From Baseline in Overall Treatment Satisfaction (OTS) at Week 26, The Overall Treatment Satisfaction is a sum of 6 items from the Diabetes Treatment Satisfaction Questionnaire, which is a self-assessment of treatment satisfaction. The scale of each sub-item goes from 0 (lowest satisfaction) to 6 (highest satisfaction) and the overall scale of OTS therefore goes from 0 to 36., Week 0, Week 26|Mean Change From Baseline in Overall Treatment Satisfaction (OTS) at Week 52, The Overall Treatment Satisfaction is a sum of 6 items from the Diabetes Treatment Satisfaction Questionnaire, which is a self-assessment of treatment satisfaction. The scale of each sub-item goes from 0 (lowest satisfaction) to 6 (highest satisfaction) and the overall scale of OTS therefore goes from 0 to 36., Week 0, Week 52|Mean Change in Overall Treatment Satisfaction (OTS) From Week 52 to Week 78, The Overall Treatment Satisfaction is a sum of 6 items from the Diabetes Treatment Satisfaction Questionnaire, which is a self-assessment of treatment satisfaction. The scale of each sub-item goes from 0 (lowest satisfaction) to 6 (highest satisfaction) and the overall scale of OTS therefore goes from 0 to 36., Week 52, Week 78|Hypoglyceamic Episodes, Weeks 0-26, Number of hypoglycaemic episodes from Week 0 to Week 26, defined as major, minor, or symptoms only. Major if unable to treat her/himself. Minor if able to treat her/himself and plasma glucose below 3.1 mmol/L. Symptoms only if able to treat her/himself and no plasma glucose measurement or plasma glucose higher than or equal to 3.1 mmol/L., Weeks 0-26|Hypoglycaemic Episodes (Excluding Outlier Subject), Weeks 0-26, Number of hypoglycaemic episodes from Week 0 to Week 26, defined as major, minor, or symptoms only. Major if unable to treat her/himself. Minor if able to treat her/himself and plasma glucose below 3.1 mmol/L. Symptoms only if able to treat her/himself and no plasma glucose measurement or plasma glucose higher than or equal to 3.1 mmol/L., Weeks 0-26|Hypoglyceamic Episodes, Weeks 0-52, Number of hypoglycaemic episodes from Week 0 to Week 52, defined as major, minor, or symptoms only. Major if unable to treat her/himself. Minor if able to treat her/himself and plasma glucose below 3.1 mmol/L. Symptoms only if able to treat her/himself and no plasma glucose measurement or plasma glucose higher than or equal to 3.1 mmol/L., Weeks 0-52|Hypoglycaemic Episodes (Excluding Outlier Subject), Weeks 0-52, Number of hypoglycaemic episodes from Week 0 to Week 52, defined as major, minor, or symptoms only. Major if unable to treat her/himself. Minor if able to treat her/himself and plasma glucose below 3.1 mmol/L. Symptoms only if able to treat her/himself and no plasma glucose measurement or plasma glucose higher than or equal to 3.1 mmol/L., Weeks 0-52|Hypoglyceamic Episodes, Weeks 0-78, Number of hypoglycaemic episodes from Week 0 to Week 78, defined as major, minor, or symptoms only. Major if unable to treat her/himself. Minor if able to treat her/himself and plasma glucose below 3.1 mmol/L. Symptoms only if able to treat her/himself and no plasma glucose measurement or plasma glucose higher than or equal to 3.1 mmol/L., Weeks 0-78|Hypoglycaemic Episodes (Excluding Outlier Subject), Weeks 0-78, Number of hypoglycaemic episodes from Week 0 to Week 78, defined as major, minor, or symptoms only. Major if unable to treat her/himself. Minor if able to treat her/himself and plasma glucose below 3.1 mmol/L. Symptoms only if able to treat her/himself and no plasma glucose measurement or plasma glucose higher than or equal to 3.1 mmol/L., Weeks 0-78|Hypoglycaamic Episodes, Weeks 52-78, Number of hypoglycaemic episodes from Week 52 to Week 78, defined as major, minor, or symptoms only. Major if unable to treat her/himself. Minor if able to treat her/himself and plasma glucose below 3.1 mmol/L. Symptoms only if able to treat her/himself and no plasma glucose measurement or plasma glucose higher than or equal to 3.1 mmol/L., Week 52-78
|
| Locations: |
Novo Nordisk Investigational Site, Birmingham, Alabama, 35242, United States|Novo Nordisk Investigational Site, Escondido, California, 92025, United States|Novo Nordisk Investigational Site, Fresno, California, 93720, United States|Novo Nordisk Investigational Site, Huntington Beach, California, 92646, United States|Novo Nordisk Investigational Site, Long Beach, California, 90822, United States|Novo Nordisk Investigational Site, Northridge, California, 91325, United States|Novo Nordisk Investigational Site, Orange, California, 92869, United States|Novo Nordisk Investigational Site, Poway, California, 92064, United States|Novo Nordisk Investigational Site, Walnut Creek, California, 94598, United States|Novo Nordisk Investigational Site, Denver, Colorado, 80209, United States|Novo Nordisk Investigational Site, Crystal River, Florida, 34429, United States|Novo Nordisk Investigational Site, Jacksonville, Florida, 32205, United States|Novo Nordisk Investigational Site, Jacksonville, Florida, 32216, United States|Novo Nordisk Investigational Site, Miami, Florida, 33169, United States|Novo Nordisk Investigational Site, Ocala, Florida, 34471, United States|Novo Nordisk Investigational Site, Panama City, Florida, 32401, United States|Novo Nordisk Investigational Site, St. Cloud, Florida, 34769, United States|Novo Nordisk Investigational Site, Athens, Georgia, 30606, United States|Novo Nordisk Investigational Site, Atlanta, Georgia, 30342, United States|Novo Nordisk Investigational Site, Dunwoody, Georgia, 30338, United States|Novo Nordisk Investigational Site, Lithia Springs, Georgia, 30122, United States|Novo Nordisk Investigational Site, Honolulu, Hawaii, 96814, United States|Novo Nordisk Investigational Site, Boise, Idaho, 83702, United States|Novo Nordisk Investigational Site, Chicago, Illinois, 60616, United States|Novo Nordisk Investigational Site, Shawnee Mission, Kansas, 66204, United States|Novo Nordisk Investigational Site, Metairie, Louisiana, 70002, United States|Novo Nordisk Investigational Site, Hyattsville, Maryland, 20782, United States|Novo Nordisk Investigational Site, Minneapolis, Minnesota, 55416, United States|Novo Nordisk Investigational Site, Cleveland, Mississippi, 38732, United States|Novo Nordisk Investigational Site, St. Peters, Missouri, 63376, United States|Novo Nordisk Investigational Site, Las Vegas, Nevada, 89109, United States|Novo Nordisk Investigational Site, Berlin, New Jersey, 08009, United States|Novo Nordisk Investigational Site, Northport, New York, 11768, United States|Novo Nordisk Investigational Site, Rosedale, New York, 11422, United States|Novo Nordisk Investigational Site, Pinehurst, North Carolina, 28374, United States|Novo Nordisk Investigational Site, Tabor City, North Carolina, 28463, United States|Novo Nordisk Investigational Site, Cincinnati, Ohio, 45245, United States|Novo Nordisk Investigational Site, Columbus, Ohio, 43201, United States|Novo Nordisk Investigational Site, Cuyahoga Falls, Ohio, 44223, United States|Novo Nordisk Investigational Site, Dayton, Ohio, 45406, United States|Novo Nordisk Investigational Site, Dayton, Ohio, 45439, United States|Novo Nordisk Investigational Site, Mentor, Ohio, 44060, United States|Novo Nordisk Investigational Site, Eugene, Oregon, 97404, United States|Novo Nordisk Investigational Site, Altoona, Pennsylvania, 16602, United States|Novo Nordisk Investigational Site, Norristown, Pennsylvania, 19401, United States|Novo Nordisk Investigational Site, Kingsport, Tennessee, 37660, United States|Novo Nordisk Investigational Site, Arlington, Texas, 76014, United States|Novo Nordisk Investigational Site, Dallas, Texas, 75230, United States|Novo Nordisk Investigational Site, Houston, Texas, 77024, United States|Novo Nordisk Investigational Site, Houston, Texas, 77030, United States|Novo Nordisk Investigational Site, Hurst, Texas, 76054, United States|Novo Nordisk Investigational Site, New Braunfels, Texas, 78130, United States|Novo Nordisk Investigational Site, San Antonio, Texas, 78229, United States|Novo Nordisk Investigational Site, Sugar Land, Texas, 77479, United States|Novo Nordisk Investigational Site, Ogden, Utah, 84403, United States|Novo Nordisk Investigational Site, St. George, Utah, 84790, United States|Novo Nordisk Investigational Site, South Burlington, Vermont, 05403, United States|Novo Nordisk Investigational Site, Newport News, Virginia, 23606, United States|Novo Nordisk Investigational Site, Richmond, Virginia, 23294, United States|Novo Nordisk Investigational Site, Milwaukee, Wisconsin, 53209, United States|Novo Nordisk Investigational Site, Edmonton, Alberta, T5A 4L8, Canada|Novo Nordisk Investigational Site, Vancouver, British Columbia, V5Z 1M9, Canada|Novo Nordisk Investigational Site, London, Ontario, N6G 2M1, Canada|Novo Nordisk Investigational Site, Newmarket, Ontario, L4Y 8E3, Canada|Novo Nordisk Investigational Site, Ottawa, Ontario, K1N 6N5, Canada|Novo Nordisk Investigational Site, Toronto, Ontario, M3J 1N2, Canada|Novo Nordisk Investigational Site, Toronto, Ontario, M5C 2T2, Canada|Novo Nordisk Investigational Site, Toronto, Ontario, M5T 3L9, Canada|Novo Nordisk Investigational Site, Montreal, Quebec, H2W 1T8, Canada|Novo Nordisk Investigational Site, Montreal, Quebec, H3J 2V5, Canada|Novo Nordisk Investigational Site, Hamilton, L8M 1K7, Canada|Novo Nordisk Investigational Site, Karlovac, 47000, Croatia|Novo Nordisk Investigational Site, Sisak, 44000, Croatia|Novo Nordisk Investigational Site, Slavonski Brod, 35 000, Croatia|Novo Nordisk Investigational Site, Belgrade, 11000, Former Serbia and Montenegro|Novo Nordisk Investigational Site, Nis, 18000, Former Serbia and Montenegro|Novo Nordisk Investigational Site, LA ROCHE-sur-YON cedex 9, 85295, France|Novo Nordisk Investigational Site, LA ROCHELLE cedex, 17019, France|Novo Nordisk Investigational Site, Limoges, 87042, France|Novo Nordisk Investigational Site, Narbonne, 11108, France|Novo Nordisk Investigational Site, Rennes, 35056, France|Novo Nordisk Investigational Site, Saint Mandé, 94160, France|Novo Nordisk Investigational Site, Strasbourg, 67000, France|Novo Nordisk Investigational Site, Venissieux, 69200, France|Novo Nordisk Investigational Site, Bad Lauterberg, 37431, Germany|Novo Nordisk Investigational Site, Bochum, 44791, Germany|Novo Nordisk Investigational Site, Dormagen, 41539, Germany|Novo Nordisk Investigational Site, Frankfurt, 60388, Germany|Novo Nordisk Investigational Site, Herrenberg, 71083, Germany|Novo Nordisk Investigational Site, Kassel, 34117, Germany|Novo Nordisk Investigational Site, Marburg, 35039, Germany|Novo Nordisk Investigational Site, Riesa, 01587, Germany|Novo Nordisk Investigational Site, Schönebeck, 39218, Germany|Novo Nordisk Investigational Site, Ulm, 89073, Germany|Novo Nordisk Investigational Site, Völklingen, 66333, Germany|Novo Nordisk Investigational Site, Wangen, 88239, Germany|Novo Nordisk Investigational Site, Dublin 9, Ireland|Novo Nordisk Investigational Site, Dublin, DUBLIN 15, Ireland|Novo Nordisk Investigational Site, Dublin, DUBLIN 4, Ireland|Novo Nordisk Investigational Site, Dublin, DUBLIN 7, Ireland|Novo Nordisk Investigational Site, Dublin, DUBLIN 8, Ireland|Novo Nordisk Investigational Site, Catania, 95124, Italy|Novo Nordisk Investigational Site, Lucca, 55100, Italy|Novo Nordisk Investigational Site, Messina, 98123, Italy|Novo Nordisk Investigational Site, Olbia, 07026, Italy|Novo Nordisk Investigational Site, Palermo, 90123, Italy|Novo Nordisk Investigational Site, Pavia, 27100, Italy|Novo Nordisk Investigational Site, Roma, 00161, Italy|Novo Nordisk Investigational Site, Siena, 53100, Italy|Novo Nordisk Investigational Site, Trieste, 34148, Italy|Novo Nordisk Investigational Site, Almere, 1311RL, Netherlands|Novo Nordisk Investigational Site, Apeldoorn, 7334 DZ, Netherlands|Novo Nordisk Investigational Site, Beek, 6191JW, Netherlands|Novo Nordisk Investigational Site, Groningen, 9728 NT, Netherlands|Novo Nordisk Investigational Site, Hengelo, 7555 DL, Netherlands|Novo Nordisk Investigational Site, Leiden, 2333 ZA, Netherlands|Novo Nordisk Investigational Site, Roelofarendsveen, 2371 RB, Netherlands|Novo Nordisk Investigational Site, Stadskanaal, 9501 EH, Netherlands|Novo Nordisk Investigational Site, Zevenaar, 6903 ZN, Netherlands|Novo Nordisk Investigational Site, Zoetermeer, 2725 NA, Netherlands|Novo Nordisk Investigational Site, Caquas, 00725, Puerto Rico|Novo Nordisk Investigational Site, Guaynabo, 00968, Puerto Rico|Novo Nordisk Investigational Site, Manati, 00674, Puerto Rico|Novo Nordisk Investigational Site, Rio Piedras, 00921, Puerto Rico|Novo Nordisk Investigational Site, Trujillo Alto, 00976, Puerto Rico|Novo Nordisk Investigational Site, Oradea, Bihor, 410469, Romania|Novo Nordisk Investigational Site, Craiova, Dolj, 200642, Romania|Novo Nordisk Investigational Site, Bucharest, 020614, Romania|Novo Nordisk Investigational Site, Timisoara, 300736, Romania|Novo Nordisk Investigational Site, Bratislava, 811 08, Slovakia|Novo Nordisk Investigational Site, Bratislava, 82102, Slovakia|Novo Nordisk Investigational Site, Bratislava, 851 05, Slovakia|Novo Nordisk Investigational Site, Nitra, 94 911, Slovakia|Novo Nordisk Investigational Site, Nove Zamky, 940 59, Slovakia|Novo Nordisk Investigational Site, Ljubljana, 1525, Slovenia|Novo Nordisk Investigational Site, Novo mesto, 8000, Slovenia|Novo Nordisk Investigational Site, Trbovlje, 1420, Slovenia|Novo Nordisk Investigational Site, Alzira, 46600, Spain|Novo Nordisk Investigational Site, Barcelona, 08036, Spain|Novo Nordisk Investigational Site, Getafe, 28905, Spain|Novo Nordisk Investigational Site, Hospitalet de Llobregat, 08907, Spain|Novo Nordisk Investigational Site, Málaga, 29010, Spain|Novo Nordisk Investigational Site, Oviedo, 33006, Spain|Novo Nordisk Investigational Site, Palma de Mallorca, 07010, Spain|Novo Nordisk Investigational Site, Palma de Mallorca, 07014, Spain|Novo Nordisk Investigational Site, Puerto del Rosario, 35600, Spain|Novo Nordisk Investigational Site, Aberdeen, AB25 1LD, United Kingdom|Novo Nordisk Investigational Site, Abergavenny, NP7 7EG, United Kingdom|Novo Nordisk Investigational Site, Aldershot, GU12 5BA, United Kingdom|Novo Nordisk Investigational Site, Ayr, KA6 6DX, United Kingdom|Novo Nordisk Investigational Site, Birmingham, B9 5SS, United Kingdom|Novo Nordisk Investigational Site, Chippenham, SN15 2SB, United Kingdom|Novo Nordisk Investigational Site, Coventry, CV6 2FL, United Kingdom|Novo Nordisk Investigational Site, Edgbaston, Birmingham, B15 2TH, United Kingdom|Novo Nordisk Investigational Site, Edinburgh, EH16 4SA, United Kingdom|Novo Nordisk Investigational Site, Edinburgh, EH4 2XU, United Kingdom|Novo Nordisk Investigational Site, Glasgow, G45 9AW, United Kingdom|Novo Nordisk Investigational Site, Leicester, LE1 5WW, United Kingdom|Novo Nordisk Investigational Site, Letchworth, SG6 4UB, United Kingdom|Novo Nordisk Investigational Site, Liverpool, L9 7AL, United Kingdom|Novo Nordisk Investigational Site, Maidstone, ME16 9QQ, United Kingdom|Novo Nordisk Investigational Site, Nottingham, NG7 2UH, United Kingdom|Novo Nordisk Investigational Site, Oxford, OX3 7LE, United Kingdom|Novo Nordisk Investigational Site, Salford, M6 8HD, United Kingdom|Novo Nordisk Investigational Site, Sheffield, S5 7AU, United Kingdom|Novo Nordisk Investigational Site, Swansea, SA6 6NL, United Kingdom
|
